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Abstract
Background: Acute pancreatitis (AP) following KT is a rare and often fatal complication of the early post-transplant
period. Common causative factors for AP are rare after KT; anti-rejection drugs as CyA, prednisone and MMF have
been implicated, although evidence is not strong and we found no reports on possible causative role for mTOR
inhibitors.
Case presentation: A 55-year-old Caucasian man with end-stage renal disease due to idiopathic membrano-
prolipherative glomerulonephritis underwent single kidney transplantation (KT) from cadaveric donor. Anti-rejection
protocol was based on Basiliximab induction followed by prednisone and mycophenolate mophetil (MMF) and
Cyclosporine; Everolimus (Eve) was scheduled to substitute MMF at week 3. At day 1 he had an asymptomatic
elevation of pancreatic enzymes, spontaneously resolved. The further course was unremarkable and on day 19 he
started Eve, with following asymptomatic rise in pancreatic enzymes. At day 33 the patient presented with
abdominal pain and a marked elevation in serum amylase (1383 U/l) and lipase (1015 U/l), normal liver enzymes
and bilirubin, no hypercalcemia, mild elevation in triglycerids; RT-PCRs for Cytomegalovirus or Epstein-Barr virus
were negative. The patient had no history of alcohol abuse; ultrasound, CT and MRI found no evidence of biliary
lithiasis. CT scans showed a patchy fluid collection in the pancreatic head area, consistent with idiopathic
necrotizing pancreatitis. The patient was treated medically and Eve was withdrawn 1 week after. Patient underwent
guided drainage of the fluid collection, but developed bacterial sepsis; surgical intervention was required with
debridement of necrotic tissue, lavage and drainage; immunosuppression was totally withdrawn. Following course
was complicated with multiple systemic infection. Transplantectomy for acute rejection was performed, and patient
entered hemodialysis.
Conclusions: Our patient had a presentation that is consistent for a causative role of Eve. A predisposing condition
(acute pancreatic insult during transplant surgery) spontaneously resolved, relapsed and evolved rapidly
in AP after the initiation of treatment with Eve with a consistent time latency. None of the well-known
common causative factors for AP was present. We discourage the use of Eve in patients with recent
episodes of sub-clinical pancreatitis, since it may represent a precipitating factor or interfere with resolution.
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Background
Since its first description by Starlz in 1964 [1], acute
pancreatitis (AP) following kidney transplantation (KT)
has been recognized as a rare and often fatal complica-
tion of the early post-transplant period, with incidence
rates reported ranging from 1 to 7 %, and an extremely
high mortality rate (from 60 to 100 %) [2–4]. AP in the
post-transplant patient represents a more complex
clinical challenge with respect to the general popula-
tion: causative factors might be different and often
unrecognized, mitigated early clinical symptoms in
immunosuppressed patients make early diagnosis and
determination of the severity of AP more difficult,
and there is no consensus on the more appropriate
treatment timing and strategy. With regard to pos-
sible etiologies, common causative factors (biliar lith-
iasis, alcohol abuse) are not frequent in the transplant
population; iatrogenic causes have been advocated,
and immunosuppressive therapy must be taken into
consideration. While there is a definite causative role
for Azathioprine and (although less, and especially regard-
ing dexamethasone) for steroids [5, 6], things appear more
uncertain for cyclosporine and mycophenolate [7]; we
found no reports about supposed causative role for mTOR
inhibitors in the pathogenesis of AP after KT.
Case presentation
A 55-year-old Caucasian man with end-stage renal dis-
ease due to idiopathic membrano-prolipherative glomer-
ulonephritis, who had been in chronic renal replacement
therapy with hemodialysis for 8 years, underwent single
kidney transplantation from cadaveric donor. The pa-
tient had a distal abdominal aortic aneurysm corrected
with endoprosthesis, and had had a previous surgical
correction of a common iliac artery aneurysm (contralat-
eral to the graft positioning); he had no previous history
of pancreatitis, gallbladder or biliary lithiasis. He had no
family history of pancreatic or biliary disorders.
Induction treatment for transplantation consisted in
Basiliximab, prednisone and mycophenolate mophetil
(MMF); after surgery, he presented delayed graft func-
tion that required two consecutive dialytic sessions. Of
note, at day 1 after transplant (while anuric) he had an
asymptomatic elevation of pancreatic enzymes (peak of
serum amylase: 718 U/l), that gradually resolved in
5 days. From day 8 he started receiving cyclosporine.
The patient also received anti-CMV prophylaxis with
Valaciclovir. The further course was unremarkable, and
the patient was regularly discharged at day 14 with a
serum creatinine of 2,1 mg/dl. However, 5 days after he
presented at follow up visit with colic pain involving the
upper right quadrant of the abdomen; an abdominal ultra-
sonography showed a normally distended gallbladder, with
no dilatation of the common bile duct or biliary three; he
had no frank elevation of pancreatic enzymes. The patient
received a course of antibiotics for evidence of pneumonia
at chest X-ray. On that day, he started Everolimus, (the
patients was enrolled in a trial that addressed the possibil-
ity of minimizing calcineurin inhibitors nephrotoxicity
with the use of mTOR inhibitors); the target through-
levels for immunouppressors were 8 ng/dl for Everolimus
and 300 ng/dl for Cyclosporine. After two more weeks the
patients had an episode of diarrhea; MMF was withdrawn
(following the study protocol), and Everolimus dose was
increased to reach target levels (on that day, blood level
was 5,11 ng/ml). The patient had mild elevation in pan-
creatic enzymes, asymptomatic, since the beginning of
treatment with Everolimus (Fig. 1). There was also evi-
dence of mild rise in serum triglycerides (ranging from
240 to 330 mg/dl) with normal total and LDL cholesterol,
for which appropriate dietary advice was preferred to
lipid-lowering treatment, according to current guidelines
[8]. On day 34 after KT, the patient presented to the emer-
gency department with pain at the upper quadrants of the
abdomen; he had marked elevation of pancreatic enzymes
(serum amylase 1383 U/l, serum lipase 1015 U/l), no ele-
vation in liver enzymes or bilirubin, mild leukocytosis
(white blood cells count: 10,13 × 103/ul), no hypercalcemia
(serum calcium 8,2 mg/dl), moderate elevation in triglyc-
erides (400 mg/dl); RT-PCRs for Cytomegalovirus or
Epstein-Barr virus were negative; at presentation APA-
CHE score II was 10 points, and after 48 h RANSON
score was 4. The patient had no history of alcohol abuse;
ultrasound, CT and MRI found no evidence of biliary tract
or gallbladder lithiasis. CT abdominal scans confirmed the
presence of a patchy fluid collection in the pancreatic head
area, extending to gastric antrum and duodenum and pos-
teriorly to the right iliopsoas muscle (Fig. 2). A diagnosis
of idiopathic necrotizing pancreatitis was made. The
patient was treated medically, and immunosuppressive
therapy initially maintained (with lowered target levels) in
Fig. 1 Trends of pancreatic enzymes since KT
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the attempt of protecting graft function; although, consid-
ered the scarce improvement, Everolimus was withdrawn
1 week after the beginning of symptoms and mild im-
munosuppression continued with Cyclosporine and ster-
oid intravenously. Graft function after initial worsening
remained stable (creatinine 2,5 mg/dl). After 1 week of
unsuccessful medical treatment, the patient underwent
CT-guided drainage of the fluid collection in the pancre-
atic head, procedure that was repeated three times in the
first month. The course was complicated by infection of
the fluid collection with Staphylococcus Haemolyticus
and Staphylococcus Epidermidis, and subsequent develop-
ment of inflammatory systemic response and sepsis. The
patient underwent surgical intervention with debridement
of necrotic tissue, lavage and drainage 45 days after the
beginning of symptoms; at that point, immunosuppressive
treatment was totally omitted. Following course was com-
plicated with multiple systemic infection with Stenotro-
phomonas Spp, Klebsiella Spp, Pseudomonas Spp,
Candida spp which required prolonged combination anti-
biotic therapy. After one more month of medical care an
allograft biopsy was performed for worsening kidney func-
tion and acute abdominal pain; histologic examination
showed signs of Banff type II acute rejection with diffuse
hemorrhagic and infarction areas. Transplantectomy was
performed, and patient restarted on hemodialysis. The pa-
tient eventually survived infections, and was discharged
after 5 months.
Discussion
AP is a well known complication following KT. Besides
traditional etiologies (biliary tract stones, alcohol,
hypertriglyceridemia, hypercalcemia), a number of pos-
sible contributing factors have been proposed in the
renal transplant patient: surgical trauma, corticosteroids
(especially pulse therapy), viral infections, immunosup-
pressive drugs. Although among the causative factors for
AP adverse drug reactions are considered to be rare, the
exclusion of all the common etiologies imposes this
evaluation.
The diagnosis of drug-induced AP is difficoult to
establish, mainly due to the absence of cause-specific
diagnostic tests, and it is usually based on the following
criteria: AP occurring during the administration of a
drug and with compatible latency time, exclusion of all
other common causes, disappearance of symptoms of
AP after drug withdrawal and symptoms recurrence
after re-challenge with suspected drug [5, 7].
Many of the commonly used maintenance immuno-
suppressive medications (azathioprine, cyclosporine,
prednisone, MMF) have been implicated clinically and
experimentally in the cause of AP. Azathioprine (which
is not currently used nowadays) is thought to have the
strongest association, and is classified as class I medica-
tion (implicated in greater than 20 reported cases of AP
with at least one documented case following re-
exposure) [5]. Cyclosporine is classified as class III drug
(only 2 published case reports giving the dosage and
latency are required to be in this category) [6]; neverthe-
less, one study involving 466 KT recipients showed an
apparent proclivity of Cyclosporine-treated patients to
develop biliary calculous disease [9]. MMF has only one
report for probable causation of AP after KT [7].
We found no reports about the possible causative role
of AP after KT for mTOR inhibitors. Nevertheless,
Subramaniam et al [10] reported the case of a young
man who developed severe hypertriglyceridemia (serum
triglycerides greater than 1000 mg/dl) and acute pan-
creatitis after a 2 months treatment course of everolimus
for metastatic pancreatic neuroendocrine tumor; of note,
everolimus is signaled to have an experimentally proven
synergistic negative effect with Cyclosporine on pancre-
atic islet dysfunction in rats [11].
When compared with general population, AP after
KT has a more serious course; whereas in non-
immunosuppressed patients overall mortality is about
5–10 %, in renal transplant patients the average mor-
tality is 61,3 % while in cases of necrotizing AP
reaches 100 % [2, 4, 12]. Necrotizing form of AP is more
frequent following KT [4, 13]. Although experimental evi-
dence is lacking, diminished immunocompetence and de-
fective macrophage and neutrophil chemotactic and
phagocytic function in KT patient may result in an initially
attenuated inflammatory response with decreased tissue
perfusion and delayed, ineffective clearance of damaged tis-
sue with consequent expansion of extensive necrosis and
infection. KT recipients have a more insidious onset of ill-
ness with fewer signs and symptoms, and the clinical pres-
entation can be misleading [2, 4].
Fig. 2 Abdominal CT Scan showing the initial area of patchy
necrosis around the head of pancreas
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Our patient had a presentation that was consistent for a
causative role of Everolimus for the development of AP.
Although there are an obvious number of confounding
factor, our patient appeared to have had a predisposing
condition (acute pancreatic insult possibly during/after
transplant surgery spontaneously resolved and not
aggravated by initial immunosuppressive treatment) that
relapsed rapidly after the initiation of treatment with
everolimus (peaking with its maximum dosage). There
was a consistent time latency (14 days) for everolimus as
causative agent or at least the last and preponderant pre-
cipitating factor. None of the well-known common risk
factors for AP was present in our patients neither before
neither at the moment of AP presentation: he had no bile
tract or gallbladder lithiasis (as shown by repeated CT and
MRI exams), no history of alcohol abuse, no hypercalce-
mia, no active viral infections. He only developed modest
hypertriglyceridemia (known complication of mTOR in-
hibitor therapy), that is not sufficient itself to justify the
clinical presentation of acute necrotizing pancreatitis [14].
The history of our patient had a tumultuous course
mainly due to the delay in surgical intervention and with-
drawal of immunosuppressive treatment, justified by the
strenuous effort to save the graft, according to patient’s
will. Our supposed association between everolimus treat-
ment and AP lacks the strength of a remission after with-
drawal of therapy. This is due in our opinion to two
reasons: the lack of recognition of this possible association
(never mentioned in literature before) and superimposed
infection that lately conditioned the gravity of clinical pic-
ture. Obviously, re-challenge with the supposed causative
drug was not attempted. Our patient ultimately survived
but lost the graft for a non-renal complication and pos-
sibly avoidable cause. The patient gave informed consent
on the publication of data.
Conclusions
In conclusion, we present the case of acute necrotiz-
ing pancreatitis 1 month after kidney transplantation
after the introduction of Everolimus and without evi-
dence of any other common causative factor for AP.
Our patient had a previous post-surgical episode of
asymptomatic and spontaneously resolved elevation in
pancreatic enzymes and enzyme levels slowly started
to rise shortly after Everolimus treatment was com-
menced. We warn clinicians to have a high degree of
suspicion for AP in KT transplant patients and pos-
sibly avoid mTOR inhibitors in patients who had pre-
vious episodes of subclinical pancreatitis, since it may
represent a precipitating factor.
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